IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Trinity Biotech plc (“Trinity” or the “Company”) (Nasdaq: TRIB) concerning possible violations of federal securities laws.
If you purchased shares of Trinity and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation concerns whether Trinity and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 4, 2016, the Company announced that it will withdraw its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the U.S. Food & Drug Administration. The Company also stated that it would reduce spending by nearly 85% and that it would close a Swedish facility, eliminating 40 jobs. When this news was released to the public, shares of Trinity declined in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.